
Postdoc in the @SilvioGutkind Lab @UCSDCancer 🇺🇸 Marie-Curie Fellow 🇪🇺🇮🇹
San Diego, CA USA
Joined January 2011
- Tweets16
- Following84
- Followers53
- Likes36
Simone Lubrano retweeted
Our Gutkind lab featured in the newspaper in Livorno, Italy, thanks to former postdoc @SimoneLubrano , for his Early Career Award from the Society for Melanoma Research @SocietyMelanoma! Grazie Simone!
Simone Lubrano retweeted
We are proud to recognize two outstanding researchers honored at the recent Society for Melanoma Research (SMR) International Congress.
The Christopher J. Marshall Award was presented to Dr. Simone Lubrano, PhD (University of Pisa, Italy and UCSF) for his recent research achievements and publications including “FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma,” recently published in Cancer Cell. nam11.safelinks.protection.o…
The Young Investigator Award was awarded to Dr. Joanna Poźniak, PhD (VIB-KU Leuven, Laboratory for Molecular Cancer Biology, Belgium) for her research accomplishments and Cancer Discovery publication “Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-excluded Phenotype”. nam11.safelinks.protection.o…
Both awards highlight the MRF’s commitment to melanoma research advancements and supporting the next generation of scientific leaders driving innovation and progress in the field.
Learn more about all MRF funded research here: melanoma.org/research-scienc…
Photo 1: Dr. Joanna Pozniak, PhD, with Bonnie Teng, PhD, Kyleigh LiPira and Dr. Liz Patton, PhD.
Photo 2: Dr. Simone Lubrano, PhD, with Bonnie Teng, PhD, Kyleigh LiPira and Dr. Liz Patton, PhD.
Simone Lubrano retweeted
Melanoma resists BRAF-targeted treatments, but combining avutometinib with FAK inhibitors may help overcome it.
MCC's AD of Basic Science, @SilvioGutkind, explores this in a recent @Cancer_Cell publication: bit.ly/4bm57Ut.
Simone Lubrano retweeted
✍️#Melanoma Combination therapy overcomes treatment resistance in #melanoma
📢Interview with @SilvioGutkind @SimoneLubrano (UC San Diego).
👉bioworld.com/articles/717550… Researchers uncover a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation.
Simone Lubrano retweeted
Online Now: FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma dlvr.it/TJDjXw
Simone Lubrano retweeted
Now, @SimoneLubrano from @SilvioGutkind's lab @UCSDCancer is telling us about drug combinations to overcome resistance to BRAF/MEK inhibitors and immunotherapy in #melanoma #TraineeMeeting @SocietyMelanoma – at New Orleans, LA
Simone Lubrano retweeted
Farewell cake for Sally and Simone @SimoneLubrano ! Many many thanks for your contributions to our lab! It was a privilege working with you! Celebrating your accomplishments, and your many amazing discoveries to come. Thanks! Cheers!
Simone Lubrano retweeted
#InViaggioconlaRicerca🇺🇲: grazie a una borsa iCARE-2 sostenuta da AIRC e dalla UE, Simone Lubrano si trova al Moores Cancer Center dell’Università della California a San Diego per studiare il melanoma uveale, un tumore dell'occhio ancora poco curabile
➡ bit.ly/2XaL3Ac















